NRIX Overview

Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, aimed at improving treatment options for patients with cancer and autoimmune diseases. The Company's wholly owned, clinical stage pipeline includes degraders of Bruton’s tyrosine kinase (BTK), a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. The Company's portfolio of targeted protein degraders of the B‑cell signaling protein BTK comprises bexobrutideg (NX‑5948) and zelebrudomide (NX‑2127). The Company's degradation inhibitor program includes NX-1607, an orally bioavailable inhibitor of CBL-B, an E3 ligase that regulates the activation of multiple immune cell types including T cells and NK cells. NX-1607 is targeted for immuno-oncology indications.

Wall Street analysts forecast NRIX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NRIX is31.08 USD with a low forecast of 22.00 USD and a high forecast of 41.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Nurix Therapeutics Inc revenue for the last quarter amounts to 6.25M USD, decreased -66.12

Nurix Therapeutics Inc. EPS for the last quarter amounts to -0.79 USD, increased 17.91

Nurix Therapeutics Inc (NRIX) has 317 emplpoyees as of May 10 2026.

Today NRIX has the market capitalization of 1.71B USD.